Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAD52 | P43351 | 1/20 | 0.44 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.44 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.42 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.40 |
| ▸ | CHRNA10 | Q9GZZ6 | 1/20 | 0.40 |
| ▸ | CHRNA9 | Q9UGM1 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.38 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.38 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | GSK3B | P49841 | 2/20 | 0.37 |
| ▸ | HTR2C | P28335 | 2/20 | 0.37 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.36 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22801996 | 0.87 | MAPT (0.46) | RAD52OPRD1ADRB1USP2ALDH1A1 | |
| SCHEMBL28596325 | 0.87 | USP2 (0.49) | RAD52OPRD1SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL22801980 | 0.87 | MAPT (0.46) | RAD52OPRD1ADRB1USP2ALDH1A1 | |
| SCHEMBL1473008 | 0.87 | USP2 (0.49) | RAD52OPRD1SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL3168784 | 0.85 | RAD52 (0.44) | RAD52SLC6A4SLC6A3SLC6A2ADRB1 | |
| Hydrochloric Acid SCHEMBL2925849 | 0.84 | RAD52 (0.46) | RAD52SLC6A4SLC6A3SLC6A2ADRB1 | |
| SCHEMBL5742221 | 0.83 | OPRD1 (0.46) | RAD52OPRD1ALDH1A1HSD17B10 | |
| Terephthalamide SCHEMBL10629550 | 0.82 | OPRD1 (0.43) | ACVR1OPRD1CHRNA7CHRNA10CHRNA9 | |
| SCHEMBL28295937 | 0.82 | RAD52 (0.42) | RAD52SLC6A4SLC6A3SLC6A2GSK3B | |
| SCHEMBL18889530 | 0.81 | HSD17B3 (0.43) | RAD52SLC6A4SLC6A3SLC6A2ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070179155-A1 | N-phenyl-piperazine derivatives and methods of prophylaxis or treatment of 5ht2c receptor associated diseases | ARENA PHARMACEUTICALS, INC. | 2007-08-02 | — | — | US | claimed |
| CN-1809545-A | N-phenyl-piperazine derivatives and methods of prophylaxis or treatment of 5HT2c | ARENA PHARM INC (US) | 2006-07-26 | — | — | CN | claimed |
| EP-1644347-A1 | N-PHENYL-PIPERAZINE DERIVATIVES AND METHODS OF PROPHYLAXIS OR TREATMENT OF 5HT sb 2C /sb RECEPTOR ASSOCIATED DISEASES | Arena Pharmaceuticals, Inc. (US) | 2006-04-12 | — | — | EP | claimed |
| WO-2005016902-A1 | N-PHENYL-PIPERAZINE DERIVATIVES AND METHODS OF PROPHYLAXIS OR TREATMENT OF 5HT2C RECEPTOR ASSOCIATED DISEASES | ARENA PHARMACEUTICALS, INC. (US) | 2005-02-24 | — | — | WO | claimed |
| US-20240116885-A1 | BENZOTHIAZOLE AND QUINOLINE DERIVATIVES AND THEIR USE | SHANGHAI YAO YUAN BIOTECHNOLOGY CO., LTD. (CN) | 2024-04-11 | — | — | US | disclosed |
| US-20070179155-A1 | N-phenyl-piperazine derivatives and methods of prophylaxis or treatment of 5ht2c receptor associated diseases | ARENA PHARMACEUTICALS, INC. | 2007-08-02 | — | — | US | disclosed |
| US-20070179155-A1 | N-phenyl-piperazine derivatives and methods of prophylaxis or treatment of 5ht2c receptor associated diseases | ARENA PHARMACEUTICALS, INC. | 2007-08-02 | — | — | US | disclosed |
| US-20070179155-A1 | N-phenyl-piperazine derivatives and methods of prophylaxis or treatment of 5ht2c receptor associated diseases | ARENA PHARMACEUTICALS, INC. | 2007-08-02 | — | — | US | disclosed |
| CN-1809545-A | N-phenyl-piperazine derivatives and methods of prophylaxis or treatment of 5HT2c | ARENA PHARM INC (US) | 2006-07-26 | — | — | CN | disclosed |
| EP-1644347-A1 | N-PHENYL-PIPERAZINE DERIVATIVES AND METHODS OF PROPHYLAXIS OR TREATMENT OF 5HT sb 2C /sb RECEPTOR ASSOCIATED DISEASES | Arena Pharmaceuticals, Inc. (US) | 2006-04-12 | — | — | EP | disclosed |
| WO-2005016902-A1 | N-PHENYL-PIPERAZINE DERIVATIVES AND METHODS OF PROPHYLAXIS OR TREATMENT OF 5HT2C RECEPTOR ASSOCIATED DISEASES | ARENA PHARMACEUTICALS, INC. (US) | 2005-02-24 | — | — | WO | disclosed |
| US-6013654-A | Imidazo[1,2-A]pyridines for the treatment of CNS and cardiac diseases | PHARMACIA & UPJOHN COMPANY (US) | 2000-01-11 | — | — | US | disclosed |
| US-5912246-A | Imidazo 1,2-a!pyridines for the treatment of CNS and cardiac diseases | PHARMACIA & UPJOHN COMPANY (US) | 1999-06-15 | — | — | US | disclosed |
| EP-0809642-A1 | IMIDAZO 1,2-A]PYRIDINES FOR THE TREATMENT OF CNS AND CARDIAC DISEASES | PHARMACIA & UPJOHN COMPANY (US) | 1997-12-03 | — | — | EP | disclosed |
| WO-1996025414-A1 | IMIDAZO[1,2-A]PYRIDINES FOR THE TREATMENT OF CNS AND CARDIAC DISEASES | PHARMACIA & UPJOHN COMPANY (US) | 1996-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240116885-A1 | BENZOTHIAZOLE AND QUINOLINE DERIVATIVES AND THEIR USE | PHKA1, PHKA2, CSNK1A1 | RAD52 2041/4885ACVR1 1127/4885OPRD1 1376/4885 |
| US-20070179155-A1 | N-phenyl-piperazine derivatives and methods of prophylaxis or treatment of 5ht2c receptor associated diseases | HTR2C, HTR2A, HTR5A | RAD52 1733/4885ACVR1 1544/4885OPRD1 137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.